Article and Video CATEGORIES
Dr. Jack West is a medical oncologist and thoracic oncology specialist who is the Founder and previously served as President & CEO, currently a member of the Board of Directors of the Global Resource for Advancing Cancer Education (GRACE)
The ADAURA Trial - Potential Clinical Impact - Potentially Curative Setting in Adjuvant Therapy for Patients Post Surgery with EGFR Mutation
We are happy to present the GRACE ASCO 2020 Lung Cancer Patient Education, News and Updates series.
Dr. Jack West has a virtual discussion with Helena A. Yu, MD, Medical Oncologist with Memorial Sloan Kettering, specializing in Lung Cancer and Targeted Therapies for Lung Cancer, and David Spigel, MD, Chief Scientific Officer; Director, Lung Cancer Research Program and Principal Investigator with Sarah Cannon.
Drs. West, Yu and Spigel discuss trial updates in non small cell lung cancer. For this video, the topic is the ADAURA Trial and it's potential clinical impact; a potentially curative setting in adjuvant therapy for patients post surgery with an EGFR mutation.
To join the conversation, visit https://cancergrace.org/forum.
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Hello Linda, my name is Alexandra Beneke, I'm the Outreach Manager for GRACE. Your willingness to share your experiences and knowledge with the cancer community is truly inspiring. Your dedication to...
Recent Comments
That's…